BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 29.2% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 625,905 shares of the biotechnology company's stock after selling 257,912 shares during the period. Voya Investment Management LLC owned 0.30% of BioCryst Pharmaceuticals worth $4,707,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Eversept Partners LP lifted its position in BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after buying an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 65,213.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock worth $4,077,000 after buying an additional 541,270 shares during the last quarter. Norges Bank purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $3,947,000. Finally, Schroder Investment Management Group increased its stake in shares of BioCryst Pharmaceuticals by 523.9% during the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company's stock valued at $3,936,000 after acquiring an additional 438,887 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded up $1.89 during midday trading on Monday, hitting $10.82. 19,630,655 shares of the company were exchanged, compared to its average volume of 3,534,879. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $10.80. The company's fifty day moving average price is $7.69 and its 200-day moving average price is $7.80. The company has a market cap of $2.26 billion, a PE ratio of -17.73 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.27. During the same quarter last year, the business earned ($0.17) EPS. The business's revenue for the quarter was up 56.8% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BCRX. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 target price for the company. HC Wainwright restated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reissued a "buy" rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. Finally, JMP Securities reiterated a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $16.13.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.